{"entity":{"id":"caribou","kind":"company","name":"Caribou Biosciences","aka":[],"tldr":"CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.","summary":"Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.","asOf":"2026-09-04","links":[{"label":"ANTLER data","url":"https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t","crispr-screens"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berkeley, CA","country":"US","companyType":"cell-therapy","website":"https://www.cariboubio.com","ticker":"CRBU","investors":[],"funding":[]},"route":"/companies/caribou/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"},{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}]}}